![Jeffrey Stavenhagen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jeffrey Stavenhagen formerly worked at Therini Bio, Inc., as Chief Scientific Officer from 2019 to 2023 and Dianthus Therapeutics, Inc., as Chief Scientific Officer from 2023 to 2025.
Dr. Stavenhagen received his doctorate degree from The Trustees of Columbia University in The City of New York.
| Sociétés | Poste | Fin |
|---|---|---|
| DIANTHUS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 02/01/2025 |
Therini Bio, Inc.
 Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in halt chronic neuroinflammation and neuronal damage caused by vascular injury to treat severe neurological & retinal diseases | Directeur Technique/Scientifique/R&D | 01/12/2023 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 3 |
|---|---|
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Therini Bio, Inc.
Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in halt chronic neuroinflammation and neuronal damage caused by vascular injury to treat severe neurological & retinal diseases | Commercial Services |
Dianthus Therapeutics, Inc.
 Dianthus Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for patients with autoimmune and inflammatory diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
